American Elements Logo and U.S. Registered Trademark
Gadolinium Nitrate
Gd(NO3)3.xH2O
Product
Product Code
Order or Specifications
99% Gadolinium Nitrate
GD-N-01
 Contact American Elements
99.9% Gadolinium Nitrate
GD-N-03
 Contact American Elements
99.99% Gadolinium Nitrate
GD-N-04
 Contact American Elements
99.999% Gadolinium Nitrate
GD-N-05
 Contact American Elements
Gadolinium Nitrate is a highly water soluble crystalline Gadolinium source for uses compatible with nitrates and lower (acidic) pH. Nitrate compounds are generally soluble in water. Nitrate materials are also oxidizing agents. When mixed with hydrocarbons, nitrate compounds can form a flammable mixture. Nitrates are excellent precursors for production of ultra high purity compounds and certain catalyst and nanoscale(nanoparticles and nanopowders) materials. All metallic nitrates are inorganic salts of a given metal cation and the nitrate anion. The nitrate anion is a univalent (-1 charge) polyatomic ion composed of a single nitrogen atom ionically bound to three oxygen atoms (Symbol: NO 3) for a total formula weight of 62.05. Gadolinium is utilized for both its high magnetic moment (7.94 µB) and in phosphors and scintillators. When complexed with EDTA ligands, it is used as an injectable contrast agent for patients undergoing magnetic resonance imaging. Gadolinium Nitrate is generally immediately available in most volumes. Ultra high purity and high purity compositions improve both optical quality and usefulness as scientific standards. Nanoscale (See also Nanotechnology Information and Quantum Dots) elemental powders and suspensions, as alternative high surface area forms, may be considered. We also produce Gadolinium Nitrate Solution. Additional technical, research and safety (MSDS) information is available as is a Reference Calculator for converting relevant units of measurement.

Gadolinium is a Block F, Group 3, Period 6 element. The electronic configuration is [Xe]4f75d16s2. In its elemental form gadolinium's CAS number is 7440-54-2. The gadolinium atom has a radius of 178.7.pm and it's Van der Waals radius is unknown. Gadolinium is utilized for both its high magnetic moment (7.94µB) and in phosphors and scintillator material. When complexed with EDTA ligands, it is used as an injectable contrast agent for patients undergoing magnetic resonance imaging. Gadolinium is available as metal and compounds with purities from 99% to 99.999% (ACS grade to ultra-high purity); metals in the form of foil, sputtering target, and rod, and compounds as submicron and nanopowder.

Formula CAS No. Appearance Molecular Weight Solubility Stability
Gd(NO3)3.xH2O 52788-53-1 White 343.26 Soluble in water, moderately soluble in strong mineral acids Slightly hygroscopic
PRODUCT CATALOG Gadolinium Research, Properties, & Information Submicron & Nanopowder Tolling Ultra High Purity Sputtering Target Crystal Growth Rod, Plate, Powder, etc. MSDS
German   Korean   French   Japanese   Spanish   Chinese (Simplified)   Portuguese   Russian   Chinese (Taiwan)   Italian   Turkish   Polish   Dutch   Czech   Swedish   Hungarian   Danish   Hebrew

Production Catalog Available in 32 Countries
 
Periodic table of the elements science and academic information, elements and advanced materials data, scientific presentations and all pages, designs, concepts, logos, and color schemes herein are the copyrighted proprietary rights and intellectual property of American Elements. American Elements is a U.S. Registered Trademark. © 2001-2009. American Elements. All rights reserved.

 

Recent Research & Development for Gadolinium

  • Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Galldiks N, Ullrich R, Schroeter M, Fink GR, Kracht LW. Eur J Nucl Med Mol Imaging. 2009 Aug 7. [Epub ahead of print] PMID: 19662410 [PubMed - as supplied by publisher]

  • [MRI exploration for the evaluation of orbital implant biocolonization in children enucleated for retinoblastoma.] Douira-Khomsi W, Korchane N, Louati H, Bhouri L, Kchaou I, Ben Hassine L, Bouguila H, Ayed S, Bellagha I. J Fr Ophtalmol. 2009 Aug 4. [Epub ahead of print] French. PMID: 19660832 [PubMed - as supplied by publisher]

  • Magnetic resonance imaging of mesenchymal stem cells labeled with dual (MR and fluorescence) agents in rat spinal cord injury. Shen J, Zhong XM, Duan XH, Cheng LN, Hong GB, Bi XB, Liu Y. Acad Radiol. 2009 Sep;16(9):1142-54. PMID: 19660710 [PubMed - in process]

  • Cerebral ischemia-reperfusion injury in rats-A 3 T MRI study on biphasic blood-brain barrier opening and the dynamics of edema formation. Pillai DR, Dittmar MS, Baldaranov D, Heidemann RM, Henning EC, Schuierer G, Bogdahn U, Schlachetzki F. J Cereb Blood Flow Metab. 2009 Aug 5. [Epub ahead of print] PMID: 19654585 [PubMed - as supplied by publisher]

  • Dynamic Contrast-Enhanced Perfusion MR Imaging With SPIO: A Pilot Study. Amemiya S, Akahane M, Aoki S, Abe O, Kamada K, Saito N, Ohtomo K. Invest Radiol. 2009 Jul 31. [Epub ahead of print] PMID: 19652616 [PubMed - as supplied by publisher]

  • [Spectroscopic analysis of Nd:GGG laser crystal] Zeng FM, Zhang Y, Sun J, Liu JH. Guang Pu Xue Yu Guang Pu Fen Xi. 2009 May;29(5):1323-6. Chinese. PMID: 19650481 [PubMed - in process]

  • A patient with acute myeloblastic leukemia who presented with conus medullaris syndrome and review of the literature. Olcay L, Arbas BK, Gökçe M. J Pediatr Hematol Oncol. 2009 Jun;31(6):440-7. PMID: 19648794 [PubMed - in process]

  • Inhibitory role of toll-like receptors agonists in Plasmodium yoelii liver stage development. Chen J, Xu W, Zhou T, Ding Y, Duan J, Huang F. Parasite Immunol. 2009 Aug;31(8):466-73. PMID: 19646211 [PubMed - in process]

  • Feasibility of T(2) (*) mapping for the evaluation of hip joint cartilage at 1.5T using a three-dimensional (3D), gradient-echo (GRE) sequence: A prospective study. Bittersohl B, Hosalkar HS, Hughes T, Kim YJ, Werlen S, Siebenrock KA, Mamisch TC. Magn Reson Med. 2009 Jul 30. [Epub ahead of print] PMID: 19645008 [PubMed - as supplied by publisher]

  • Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Mavrogeni S, Manoussakis MN, Karagiorga TC, Douskou M, Panagiotakos D, Bournia V, Cokkinos DV, Moutsopoulos HM. Arthritis Rheum. 2009 Jul 30;61(8):1121-1129. [Epub ahead of print] PMID: 19644909 [PubMed - as supplied by publisher]

  • Potential side effects of gadolinium-enhanced MRI . Smith SM, Hoag SD. Am Fam Physician. 2009 Aug 1;80(3):214. No abstract available. PMID: 19642251 [PubMed - in process]

  • Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Kawate T, Michel JC, Birdsong WT, Gouaux E. Nature. 2009 Jul 30;460(7255):592-8. PMID: 19641588 [PubMed - indexed for MEDLINE]

  • Clinical evaluation of magnetic resonance imaging in coronary heart disease: The CE-MARC study. Greenwood JP, Maredia N, Radjenovic A, Brown JM, Nixon J, Farrin AJ, Dickinson C, Younger JF, Ridgway JP, Sculpher M, Ball SG, Plein S. Trials. 2009 Jul 29;10(1):62. [Epub ahead of print] PMID: 19640271 [PubMed - as supplied by publisher]

  • Motexafin gadolinium: a novel radiosensitizer for brain tumors. Francis D, Richards GM, Forouzannia A, Mehta MP, Khuntia D. Expert Opin Pharmacother. 2009 Jul 29. [Epub ahead of print] PMID: 19640206 [PubMed - as supplied by publisher]

  • Effect of intravenous gadolinium-DTPA on diffusion tensor MR imaging for the evaluation of brain tumors. Bae MS, Jahng GH, Ryu CW, Kim EJ, Choi WS, Yang DM. Neuroradiology. 2009 Jul 28. [Epub ahead of print] PMID: 19636547 [PubMed - as supplied by publisher]

  • Mural Inflammation in Crohn Disease: Location-Matched Histologic Validation of MR Imaging Features. Punwani S, Rodriguez-Justo M, Bainbridge A, Greenhalgh R, De Vita E, Bloom S, Cohen R, Windsor A, Obichere A, Hansmann A, Novelli M, Halligan S, Taylor SA. Radiology. 2009 Jul 27. [Epub ahead of print] PMID: 19635832 [PubMed - as supplied by publisher]

  • Juxta-articular myxoma within the suprapatellar pouch masquerading as a ganglion cyst. Kosty JW, Moore JG. Orthopedics. 2009 Jul;32(7):527. doi: 10.3928/01477447-20090527-27. PMID: 19634839 [PubMed - in process]

  • The Evolution of Osseous Metaplasia in Localized Cutaneous Nephrogenic Systemic Fibrosis: A Case Report. Wiedemeyer K, Kutzner H, Abraham JL, Thakral C, Carlson JA, Tran TA, Hausser I, Hartschuh W. Am J Dermatopathol. 2009 Jul 23. [Epub ahead of print] PMID: 19633532 [PubMed - as supplied by publisher]

  • Lumbar congestive myelopathy mimicking neoplasia without concurrent vascular malformation. Tsutsumi S, Abe Y, Yasumoto Y, Ito M. Neurol Med Chir (Tokyo). 2009 Jul;49(7):316-9. PMID: 19633406 [PubMed - in process]

  • Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy. Hombach V, Merkle N, Torzewski J, Kraus JM, Kunze M, Zimmermann O, Kestler HA, Wöhrle J. Eur Heart J. 2009 Jul 24. [Epub ahead of print] PMID: 19633015 [PubMed - as supplied by publisher]
Material Safety Data Sheet
  • 1 Identification of substance

    • Product details

    • Trade name Gadolinium nitrate
  • 2 Composition/Data on components:

    • Chemical characterization:
                 Designation: (CAS#)                                        
      Gadolinium nitrate, hydrate (CAS# ?), 100%
  • 3 Hazards identification

    • Hazard designation:
      Xi Irritant
      O  Oxidising
    • Information pertaining to particular dangers for man and environment
      R 8        Contact with combustible material may cause fire.
      R 36/37/38 Irritating to eyes, respiratory system and skin.
  • 4 First aid measures

    • After inhalation
      Supply fresh air. If required, provide artificial respiration. Keep patient warm. Consult doctor if symptoms persist.
      Seek immediate medical advice.
    • After skin contact
      Instantly wash with water and soap and rinse thoroughly.
      Seek immediate medical advice.
    • After eye contact
      Rinse opened eye for several minutes under running water. Then consult doctor.
    • After swallowing Seek immediate medical advice.
    • Information for doctor
    • The following symptoms may occur:
      Gastric or intestinal trouble
      Cramp
      Dazed
  • 5 Fire fighting measures

    • Suitable extinguishing agents
      Use fire fighting measures that suit the environment.
    • Special hazards caused by the material, its products of combustion or
        flue gases:
      Can be released in case of fire:
      Nitrogen oxides (NOx)
    • Protective equipment:
      Wear self-contained breathing apparatus.
      Wear full protective suit.
  • 6 Accidental release measures

    • Person-related safety precautions:
      Wear protective equipment. Keep unprotected persons away.
      Ensure adequate ventilation
    • Measures for environmental protection:
      Do not allow material to be released to the environment without proper governmental permits.
    • Measures for cleaning/collecting: Ensure adequate ventilation.
    • Additional information:
      See Section 7 for information on safe handling
      See section 8 for information on personal protection equipment.
      See Section 13 for information on disposal.
  • 7 Handling and storage


    • Handling
    • Information for safe handling:
      Keep containers tightly sealed.
      Store in cool, dry place in tightly closed containers.
      Ensure good ventilation/exhaustion at the workplace.
    • Information about protection against explosions and fires:
      Substance/product can reduce the ignition temperature of flammable substances.
      This substance is an oxidizer and its heat of reaction with reducing agents or combustibles may cause ignition.

    • Storage
    • Requirements to be met by storerooms and containers:
      No special requirements.
    • Information about storage in one common storage facility:
      Store away from flammable substances.
      Store away from reducing agents.
      Do not store together with acids.
    • Further information about storage conditions:
      Keep container tightly sealed.
      Store in cool, dry conditions in well sealed containers.
  • 8 Exposure controls and personal protection

    • Additional information about design of technical systems:
      Properly operating chemical fume hood designed for hazardous chemicals and having an average face velocity of at least 100 feet per minute.

    • Components with critical values that require monitoring at the
      workplace:                                                             
      Not required.
    • Additional information: No data

    • Personal protective equipment
    • General protective and hygienic measures
      The usual precautionary measures should be adhered to in handling the chemicals.
      Keep away from foodstuffs, beverages and food.
      Instantly remove any soiled and impregnated garments.
      Wash hands during breaks and at the end of the work.
      Avoid contact with the eyes and skin.
    • Breathing equipment: Use breathing protection with high concentrations.
    • Protection of hands: Impervious gloves
    • Eye protection:
      Safety glasses
      Face protection
    • Body protection: Protective work clothing.
  • 9 Physical and chemical properties:

    • General Information

    • Form: Crystalline
    • Colour: White
    • Smell: Odourless
    •   Value/Range  Unit    Method      
    • Change in condition
    • Melting point/Melting range:       Not determined
    • Boiling point/Boiling range:       Not determined
    • Sublimation temperature / start:   Not determined

    • Flash point:                       Not applicable

    • Inflammability (solid, gaseous)
      Contact with combustible material may cause fire.

    • Ignition temperature:              Not determined

    • Decomposition temperature:         Not determined

    • Critical values for explosion:
    • Lower:                             Not determined
    • Upper:                             Not determined

    • Steam pressure:                    Not determined

    • Density                            Not determined

    • Solubility in / Miscibility with
    • Water:                             Soluble
      Not determined
  • 10 Stability and reactivity

    • Thermal decomposition / conditions to be avoided:
      No decomposition if used and stored according to specifications.
    • Materials to be avoided:
      Reducing agents, easily oxidized materials
      Organic materials
      Metal powders
      Acids
    • Dangerous reactions:
      Reacts with reducing agents
      Reacts with flammable substances
    • Dangerous products of decomposition: Nitrous vitriol gases
  • 11 Toxicological information

    • Acute toxicity:
    • Primary irritant effect:
    • on the skin: Irritant for skin and mucous membranes.
    • on the eye: Irritant effect.
    • Sensitization: No sensitizing effect known.
    • Additional toxicological information:
      To the best of our knowledge the acute and chronic toxicity of this substance is not fully known.
      No classification data on carcinogenic properties of this material is available from the EPA, IARC, NTP, OSHA or ACGIH.
  • 12 Ecological information:

    • General notes:
      Do not allow material to be released to the environment without proper governmental permits.
      Water hazard class 1 (Self-assessment): slightly hazardous for water.
      Do not allow undiluted product or large quantities of it to reach ground water, water bodies or sewage system.
  • 13 Disposal considerations


    • Product:
    • Recommendation
      Consult state, local or national regulations for proper disposal.
      Hand over to disposers of hazardous waste.
      Must be specially treated under adherence to official regulations.

    • Uncleaned packagings:
    • Recommendation:
      Disposal must be made according to official regulations.
  • 14 Transport information


    • Land transport ADR/RID and GGVS/GGVE (cross-border/domestic)
    • ADR/RID-GGVS/E Class:     5.1 (O2) Oxidizing substances.
    • Kemler Number:            50
    • UN-Number:                1477
    • Packaging group:          III
    • Label                     5.1
    • Designation of goods:     1477 NITRATES, INORGANIC, N.O.S. (Gadolinium
                                 nitrate)

    • Maritime transport IMDG/GGVSea:
    • IMDG/GGVSea Class:        5.1
    • UN Number:                1477
    • Label                     5.1
    • Packaging group:          III
    • Correct technical name:   NITRATES, INORGANIC, N.O.S.

    • Air transport ICAO-TI and IATA-DGR:
    • ICAO/IATA Class:          5.1
    • UN/ID Number:             1477
    • Label                     5.1
    • Packaging group:          III
    • Correct technical name:   NITRATES, INORGANIC, N.O.S.
  • 15 Regulatory information


    • Designation according to EC guidelines:

    • Code letter and hazard designation of product:
      Xi Irritant O Oxidising

    • Risk phrases:
      8        Contact with combustible material may cause fire.
      36/37/38 Irritating to eyes, respiratory system and skin.

    • Safety phrases:
      17       Keep away from combustible material.
      26       In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

    • National regulations

    • Information about limitation of use:
      For use only by technically qualified individuals.
      Employment restrictions concerning young persons must be observed.

    • Water hazard class:
      Water hazard class 1 (Self-assessment): slightly hazardous for water.
  • 16 Other information:

      Employers should use this information only as a supplement to other information gathered by them, and should make independent judgement of suitability of this information to ensure proper use and protect the health and safety of employees.  This information is furnished without warranty, and any use of the product not in conformance with this Material Safety Data Sheet, or in combination with any other product or process, is the responsibility of the user.

    •  

    American Elements Products can also be sourced at these sites: